McGill Reproductive Centre, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill University, Royal Victoria Hospital, 687 Pine Avenue West, H3A 1A1, Montreal, Quebec, Canada.
Best Pract Res Clin Obstet Gynaecol. 2010 Feb;24(1):101-12. doi: 10.1016/j.bpobgyn.2009.11.007. Epub 2010 Feb 8.
In vitro fertilization and embryo cryopreservation is regarded as the only established method for fertility preservation in female cancer patients. However, a possible delay in treatment of the primary disease due to ovarian stimulation, exposure to supraphysiologic estrogen levels induced by ovarian stimulation, the requirement for a male partner or willingness to use donor sperm for embryo production, legal, ethical, religious issues related to cryopreservation of embryos raise concerns for patients and physicians. Recent improvements achieved with oocyte vitrification have increased the effectiveness of oocyte cryopreservation rendering it a viable option, especially for patients without a male partner. In vitro maturation avoids treatment delay or exposure to increased estradiol levels associated with ovarian stimulation for in vitro fertilization. In vitro maturation combined with embryo or oocyte vitrification provides previously unavailable options for some patients and improves the services provided by a fertility preservation program.
体外受精和胚胎冷冻被认为是女性癌症患者生育力保存的唯一成熟方法。然而，卵巢刺激可能会延迟对原发疾病的治疗，卵巢刺激引起的超生理雌激素水平的暴露，对胚胎生产所需的男性伴侣或使用供体精子的意愿，与胚胎冷冻保存相关的法律、伦理和宗教问题，都使患者和医生感到担忧。卵母细胞玻璃化技术的最新进展提高了卵母细胞冷冻的效果，使其成为一种可行的选择，尤其是对于没有男性伴侣的患者。体外成熟避免了与体外受精相关的卵巢刺激导致的治疗延迟或暴露于增加的雌二醇水平。体外成熟与胚胎或卵母细胞玻璃化相结合，为一些患者提供了以前无法获得的选择，并改善了生育力保存计划所提供的服务。
